Posted by Michael Wonder on 11 May 2021
FDA grants fast track designation to CERC-002 for treatment of hospitalised patients with COVID-19
11 May 2021 - Cerecor today announced that the U.S. FDA has granted fast track designation to CERC-002 for treatment of hospitalised patients with COVID-19.
CERC-002 is a first in class fully human monoclonal antibody targeting LIGHT (tumour necrosis factor superfamily member 14, TNFSF14).
